User profiles for X. Puechal

Xavier Puechal

Verified email at aphp.fr
Cited by 22276

Whipple's disease

F Fenollar, X Puéchal, D Raoult - New England Journal of …, 2007 - Mass Medical Soc
In 2000, Tropheryma whipplei was finally identified as the cause of Whipple's disease, a
chronic condition with protean manifestations that was first described in 1907. This review …

Ocular inflammatory diseases associated with rheumatoid arthritis

…, A Brezin, L Guillevin, X Puechal - Nature Reviews …, 2014 - nature.com
The extra-articular complications of rheumatoid arthritis (RA) include ophthalmological
manifestations, which can, in some cases, be the first signs of the disease. These inflammatory …

Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging

Y Allanore, O Vignaux, L Arnaud, X Puéchal… - Annals of the …, 2006 - ard.bmj.com
Background: Cardiac involvement in idiopathic inflammatory myopathy has been recognised
as an important prognostic factor, but treatment remains empirical. Objective: To investigate …

[HTML][HTML] Azathioprine or methotrexate maintenance for ANCA-associated vasculitis

…, M Khellaf, D Merrien, X Puéchal… - … England Journal of …, 2008 - Mass Medical Soc
Background Current standard therapy for Wegener's granulomatosis and microscopic
polyangiitis combines corticosteroids and cyclophosphamide to induce remission, followed by a …

Antineutrophil cytoplasmic antibodies and the Churg–Strauss syndrome

…, JF Cordier, P Delaval, X Puechal… - Annals of internal …, 2005 - acpjournals.org
Background: Since testing for antineutrophil cytoplasmic antibodies (ANCA) became
available for routine evaluation, no large homogeneous cohort of patients with the Churg–Strauss …

Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS)

…, E Hachulla, B Combe, X Puéchal… - … : Official Journal of …, 2004 - Wiley Online Library
Objective. There is no effective treatment for patients with primary Sjögren’s syndrome (SS).
Since tumor necrosis factor (TNF) could be a key element in the pathogenesis of primary SS, …

A multicenter, randomized, double‐blind, placebo‐controlled trial of adjuvant methotrexate treatment for giant cell arteritis

…, AM Segal, C Ludivico, X Puechal… - Arthritis & …, 2002 - Wiley Online Library
Objective To evaluate treatment with methotrexate (MTX) in patients with newly diagnosed
giant cell arteritis (GCA) to determine if MTX reduces GCA relapses and cumulative …

[HTML][HTML] Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis

…, CA Peh, WM Szpirt, X Puéchal… - … England Journal of …, 2020 - Mass Medical Soc
Background More effective and safer treatments are needed for antineutrophil cytoplasmic
antibody (ANCA)–associated vasculitis. Methods We conducted a randomized trial with a 2-by…

Treatment of primary Sjögren syndrome with rituximab: a randomized trial

…, JM Berthelot, A Perdriger, X Puéchal… - Annals of internal …, 2014 - acpjournals.org
Background: Primary Sjögren syndrome (pSS) is an autoimmune disorder characterized by
ocular and oral dryness or systemic manifestations. Objective: To evaluate efficacy and …

Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial

JE Gottenberg, P Ravaud, X Puéchal, V Le Guern… - Jama, 2014 - jamanetwork.com
Importance Primary Sjögren syndrome is a systemic autoimmune disease characterized by
mouth and eye dryness, pain, and fatigue. Hydroxychloroquine is the most frequently …